Drug Profile


Latest Information Update: 02 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kunming Pharmaceutical
  • Developer Kunming Pharmaceutical Group
  • Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Fluorenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malaria
  • Clinical Phase Unknown Schistosomiasis

Most Recent Events

  • 02 Jun 2000 Investigation in Schistosomiasis in Ivory Coast (PO)
  • 02 Jun 2000 A clinical study evaluating artemether for the prevention of schistosomiasis has been added to the therapeutic trials section
  • 26 May 2000 A study has been added to the pharamacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top